* WHY BUY * longer term potential

[Maningreen0]

Why buy - BIEL 0.0303
From the Yahoo message board by a poster named Joe Noel who is part of the company management team. Some say he is investor relations manager. His opinion is probably somewhat biased but he states alot of facts that can be backed up by doing a bit of digging. All in all a company with a lot of potential and at a great price.

Hello Everyone:

I wanted to take a minute to clear up a couple of inaccuracies on this board and to remind all of you of what's coming up out of BIEL over the short-term. None of this is nonpublic information, as we have discussed all of it previously.

We are expecting to receive the data from the heel and foot pain study any day now. Plantar fasciitis is a major problem for many people. The study was connected by Dr. David Genecov who practices out of Dallas. His bios is at http://www.genecovplasticsurgery.com/mee... - his credentials are especially impressive and we are very lucky to have him involved as the principal investigator on the study. The study was IRB supervised and registered with NIH - all of the things the FDA likes to see.

Assuming the data is good, expect us to file an additional application with the FDA over the very short term. As we have also indicated, we also expect to file an additional application with the FDA for general surgical recovery. We think we already have some very high quality data that supports this application and we think we have a very good shot of receiving the indication. We believe both of these markets are worth tens of millions of dollars per year in revenues. Considering our very strong potential gross margins (70%+), we think it's going to make an impressive impact on the company's bottom line.

We are honored that these busy MDs are taking such a strong interest in the company. There are five or six other MDs taking a similar interest in various applications - uvitis, hernia surgery recovery, breast aug, c-section recovery - we are currently not able to keep up with the demand for clinical studies - the requests are too numerous. It is incredible how much interest is developing.

Since filing the menstrual pain application with the FDA and announcing the patent a lot has changed at the company. It's been amazing how many calls we are getting from potential distributors and other partners who want information about the products and want to set up meetings about how they can work with the company. In all my years working with small-cap companies I've never seen such a significant level of “buzz” within an organization. We can see a scenario developing where BIEL shares quickly move to $.10 just based on the information we have already indicated is coming. Assuming, we receive the FDA indications we are expecting, we think the shares could trade a lot higher. We're all very excited about not only our revenue and profit generation opportunities, but also relative to maximizing shareholder value for all of the shareholders.

I also wanted to clear up the misinformation about the number of shares in the float. Almost all of the outstanding shares are free trading in the market. The information that shows the float below 200 million shares is incorrect. We don't know the exact number, we estimate that the float is somewhere over 500 million -It's difficult, however, to really pin down the exact number.

Thank you all for your continued support. It is truly a very exciting time for the management team and for everyone at BIEL. We look forward to maintaining our current momentum and to building long-term value for all shareholders.

Joe Noel